United States · FDA National Drug Code directory

Naropin

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
63323-286_324532ac-4e54-4659-a1a2-9ade22a1ed3f
Product NDC
63323-286
Form
INJECTION, SOLUTION
Composition / generic term
ROPIVACAINE HYDROCHLORIDE
Labeler
Fresenius Kabi USA, LLC
Marketing category
NDA
Marketing start / end (source format)
20090804
Source listing expiry
20261231

Source-listed ingredients

  • ROPIVACAINE HYDROCHLORIDE — 5 mg/mL

These values do not establish equivalence or a dose recommendation.

Packages

  • 25 VIAL, SINGLE-DOSE in 1 CARTON (63323-286-27) / 20 mL in 1 VIAL, SINGLE-DOSE (63323-286-41) · 63323-286-27
  • 25 VIAL, SINGLE-DOSE in 1 CARTON (63323-286-38) / 30 mL in 1 VIAL, SINGLE-DOSE (63323-286-43) · 63323-286-38

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →
Naropin — United States | Molindra Medicines